Aeglea BioTherapeutics announced it will effect a reverse stock split of all outstanding shares of Aeglea’s common stock at a ratio of 1-for-25. Aeglea expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on September 8, 2023. The reverse stock split was approved by stockholders during the annual meeting of stockholders on June 6, 2023 and by Aeglea’s Board of Directors. The reverse stock split is intended to enable the company to meet minimum Nasdaq listing price per share requirements.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AGLE:
- Aeglea BioTherapeutics appoints Burrows as CFO, King-Jones as CLO
- Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results
- Aeglea BioTherapeutics reports Q2 EPS ($2.27) vs. (27c) last year
- Aeglea BioTherapeutics files to sell 1.1M shares of common stock for holders
- AGLE Upcoming Earnings Report: What to Expect?